Quantcast

Latest Small interfering RNA Stories

2011-08-31 11:00:00

Cenix BioScience GmbH, a leading contract research provider and technology developer specialized in RNAi-, microRNA- and high content-driven pharmacology, and ugichem GmbH, a gene silencing company

2011-08-03 06:00:00

LONDON, August 3, 2011 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces that the United States Patent and Trademark Office has issued the Company a notice of allowance on a patent application directed to the fundamental technology involved in AtuPLEX(TM), one of Silence's proprietary small interfering RNA (siRNA) delivery systems.

2011-07-14 11:56:00

CARLSBAD, Calif., July 14, 2011 /PRNewswire/ -- Life Technologies Corporation today announced that it has developed new drug delivery technology specially designed for therapeutic applications that is 100-fold more potent than previous formulations.

2011-07-14 08:00:00

LA JOLLA, Calif., July 14, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has added Gregory Hannon, Ph.D. to its Scientific Advisory Board (SAB).

2011-06-23 08:18:00

GAITHERSBURG, Md., June 23, 2011 /PRNewswire/ -- Sirnaomics, Inc. (www.sirnaomics.com) announced today that the company has signed a partnership agreement with Guangdong Zhongsheng Pharmaceutical Co. Ltd., a Chinese pharmaceutical company trading on the Shenzhen Stock Exchange (SZSE: 002317).

2011-06-10 00:00:31

LC Sciences, a life sciences company leading the development of innovative microRNA (miRNA) analysis and discovery technologies, announced today the publication of over 250 peer-reviewed studies using the company’s microarray service for analyzing miRNA expression profiles.

2011-06-08 12:00:00

LA JOLLA, Calif., and CAMBRIDGE, Mass., June 8, 2011 /PRNewswire/ -- Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and Alnylam Pharmaceuticals, Inc.

2011-06-06 08:00:00

LONDON, June 6, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces positive updated data from its ongoing Phase I study of Atu027, one of the most clinically advanced RNAi therapeutics in the area of oncology, in patients with advanced solid tumors. Study results show that nine of the 24 patients treated with Atu027 to date achieved stable disease after repeated treatment...

2011-05-18 17:05:00

LONDON, May 18, 2011 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company"), a leading global RNA interference (RNAi) therapeutics company, announces that it will present new data from its ongoing Phase I study of Atu027, its lead internal therapeutic candidate, at the 2011 American Society of Clinical Oncology ("ASCO") Annual Meeting on 06 June 2011. Top-line data includes results for 21 patients who received the study's first seven escalating doses...

2011-05-16 19:16:07

Using a technique that silences genes promoting infection, researchers have developed a novel, topically-applied molecular microbicide capable of preventing HIV transmission.


Word of the Day
overword
  • To say in too many words; to express verbosely.
  • To express in too many words: sometimes used reflexively.
  • The leading idea or a repeated phrase, as of a song or ballad; the refrain; burden.
The word 'overword' comes from over- +‎ word.